Allergan plc (NYSE:AGN) price target raised to $185.00 by SunTrust Banks

Analyst Ratings For Allergan plc (NYSE:AGN)

Story continues below

Today, SunTrust Banks raised its price target on Allergan plc (NYSE:AGN) to $185.00 per share.

There are 12 Hold Ratings, 9 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Allergan plc (NYSE:AGN) is Hold with a consensus target price of $176.8395 per share, a potential 4.31% upside.

Some recent analyst ratings include

  • 6/26/2019-Allergan plc (NYSE:AGN) gets downgraded to Neutral by Mizuho with a price target of $188.00
  • 6/25/2019-Allergan plc (NYSE:AGN) had its Buy rating reiterated by Wells Fargo & Co
  • 6/25/2019-Allergan plc (NYSE:AGN) gets downgraded to Market Perform by Raymond James
  • 6/25/2019-Allergan plc (NYSE:AGN) gets upgraded to Equal Weight by Barclays
  • On 3/7/2019 Brent L Saunders, Chairman, bought 1,760 with an average share price of $143.67 per share and the total transaction amounting to $252,859.20.
  • On 11/16/2018 Matthew M. Walsh, CFO, bought 1,000 with an average share price of $157.00 per share and the total transaction amounting to $157,000.00.
  • On 9/6/2018 Christopher J. Coughlin, Director, bought 10,000 with an average share price of $190.64 per share and the total transaction amounting to $1,906,400.00.
  • On 8/30/2018 Joseph H. Boccuzi, Director, bought 900 with an average share price of $190.59 per share and the total transaction amounting to $171,531.00.
  • On 5/17/2018 William Meury, EVP, sold 24,425 with an average share price of $154.59 per share and the total transaction amounting to $3,775,860.75.
  • On 3/15/2018 Maria Teresa Hilado, Insider, bought 895 with an average share price of $167.39 per share and the total transaction amounting to $149,814.05.
  • On 3/8/2018 Brent L. Saunders, CEO, bought 3,300 with an average share price of $152.53 per share and the total transaction amounting to $503,349.00.

About Allergan plc (NYSE:AGN)
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. Read More…

Recent Trading Activity for Allergan plc (NYSE:AGN)
Shares of Allergan plc closed the previous trading session at 169.54 up +2.02 1.21% with 5185400 shares trading hands.

An ad to help with our costs